Navigation Links
Ganeden Biotech Granted 100th Probiotic Patent
Date:10/14/2010

CLEVELAND, Oct. 14 /PRNewswire/ -- Ganeden Biotech, Inc., maker of the patented probiotic strain GanedenBC30®, recently announced the granting of the company's 100th patent, which expands the use and scope of the GanedenBC30® probiotic to help prevent lactic-acid bacteria and to better improve digestive and immune health.  

The 100th patent comes in the wake of Ganeden's latest collaboration with Organic Milling marking a milestone for the company as it continues to develop new product partnerships with some of the world's most innovative food and product manufacturers.  

From Bigelow® Tea and Red Mango to Guernsey Farms Dairy and Agostoni Chocolate, Ganeden's range of products and partnerships is a testament to the versatility and durability of their probiotic strain Bacillus coagulans GBI-30, 6086 branded as GanedenBC30®, which has the unique ability to survive the harsh manufacturing process and still be activated in the body.  This is attributed to the naturally occurring layer of organic material that protects the genetic core of the bacteria throughout the manufacturing and digestion process.

"The 100th patent approval is a true accomplishment for us, as it reflects the extent of our innovation and collaboration since the GanedenBC30® probiotic was first developed and patented just a little over a decade ago," said Sean Farmer, Chief Scientific Officer and co-founder of Ganeden Biotech. Farmer is credited with discovering the GanedenBC30® probiotic and has written each subsequent patent since helping co-found the company in 1997.  "We owe our success to our unrivaled dedication to creativity and perseverance, inherent within each of our partnerships, which have enabled us to provide proven health benefits to millions of consumers via a variety of functional health products."

About Ganeden Biotech

Founded in 1997, Ganeden Biotech, Inc. is based in Cleveland, Ohio, and is the largest seller of over-the-counter probiotics in the U.S. through its Digestive Advantage® and Sustenex® brands. It also licenses its patented probiotic bacteria, GanedenBC30®, for use in commercial food and beverage applications, nutraceuticals and in animal health industries. GanedenBC30® is self-affirmed GRAS (Generally Recognized as Safe) by an independent panel of experts assembled to assess its safety in use as a food ingredient. For more information about licensing opportunities visit ganedenlabs.com and for probiotic supplement information visit digestiveadvantage.com or sustenex.com.


'/>"/>
SOURCE Ganeden Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ganeden Biotech Introduces the First Probiotic Thin Strip
2. Ganeden Biotech Introduces GanPro(TM) Direct-Fed Microbial for Livestock
3. Ganeden Biotech, Liquid Health Labs Unveil New Drink Technology
4. Ganeden Biotech and Heartland Sweeteners to Produce Probiotic Sweetener
5. Ganeden Biotech Receives Frost & Sullivan Probiotics Product Innovation Award
6. Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
7. Reportlinker Adds the Top 10 Biotechnology Companies: Positioning, Performance and SWOT Analyses
8. Trius to Participate in Antibiotics Panel Discussion at Citis 5th Annual Biotech Day
9. Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics
10. Biotech Posts Strong Third Quarter Performance as Capital Markets Go on a Tear
11. Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
Breaking Biology Technology:
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
Breaking Biology News(10 mins):